Compounding evidence: management cites customer behavior, not just customer numbers, as proof the offering is winning
The model's full reasoning — Q4 2022 call → NOWe need answer YES/NO. Need analyze transcript. Need determine if management grounds case in observed customer/counterparty behavior from recent period, concrete, current, and treats as core proof with more ahead. Need only transcript. Let's parse. Management discusses EYLEA, Dupixent, Libtayo, aflibercept 8mg, pipeline. Need find behavioral evidence of customers/counterparties doing things. Marion on EYLEA: "EYLEA category share was approaching previous levels of approximately 50% of injections. This followed short-term shift... temporary increase in use of off-label compounded Avastin... not-for-profit patient co-pay assistance fund, which reopened later in quarter. We believe we have substantially recovered from issue." That is about recovery, not necessarily positive behavior. Also "we continue to hear that first nAb use has been modest and results, in some cases, have resulted in patients switching back to other agents, including EYLEA probably most frequently EYLEA." That is observed behavior? Patients switching back to EYLEA. But is it concrete? It's hearsay "we continue to hear" and "in some cases" - not strong. Also management doesn't treat as core proof? Maybe. Dupixent: "strong growth continuing across atopic dermatitis, asthma, nasal polyps with additional contributions from recent launches... rapid uptake in younger populations... meaningful early adoption in prurigo nodularis... DUPIXENT continues to perform well in highly competitive biologic asthma space with steady market share gains and strong growth in total prescriptions and new patient starts. In nasal polyps, DUPIXENT’s differentiated clinical profile continues to drive uptake as leading first-line treatment option... eosinophilic esophagitis launch going exceptionally well... rapid uptake across both gastroenterologists and allergists." This is behavioral evidence? "rapid uptake", "new patient starts", "market share gains" - but not specific concrete behavior? It's more sales/market share metrics, not described as customers doing something revealing preference. Also "launch going exceptionally well" is generic. No specific pattern like reorders, adoption faster, etc. It's company's results. Libtayo: "Customer ordering has accelerated following chemotherapy combination approval last November. We are working to maximize launch uptake by increasing depth and breath of prescribers.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| FWONK | Formula One Group | Q1 2024 | 2024-05-08 | C+ |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| PPC | Pilgrim's Pride Corporation | Q1 2024 | 2024-05-03 | A |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| LEGH | Legacy Housing Corporation | Q4 2023 | 2024-03-18 | C |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| CHT | Chunghwa Telecom Co., Ltd. | Q4 2023 | 2024-01-30 | C |
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| AIRG | Airgain, Inc. | Q3 2023 | 2023-11-09 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| AEIS | Advanced Energy Industries, Inc. | Q2 2023 | 2023-08-03 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| FTHM | Fathom Holdings, Inc. | Q1 2023 | 2023-05-10 | C |
| ULCC | Frontier Group Holdings, Inc. | Q1 2023 | 2023-05-07 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| BLZE | Backblaze, Inc. | Q3 2022 | 2022-11-11 | D |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| MEC | Mayville Engineering Company, Inc. | Q3 2022 | 2022-11-05 | B+ |
| AWRE | Aware, Inc. | Q3 2022 | 2022-10-30 | F |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| INVH | Invitation Homes Inc. | Q2 2022 | 2022-07-28 | B+ |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| MOMO | Hello Group Inc. | Q3 2021 | 2021-11-30 | D |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| ZH | Zhihu Inc. | Q3 2021 | 2021-11-22 | D |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| DGX | Quest Diagnostics Incorporated | Q2 2021 | 2021-07-22 | B+ |
| JPM | JPMorgan Chase & Co. | Q2 2021 | 2021-07-13 | A |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| AMGN | Amgen Inc. | Q3 2018 | 2018-10-30 | B+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PCRX | Pacira BioSciences, Inc. | Q4 2017 | 2018-02-28 | C |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| MKTX | MarketAxess Holdings Inc. | Q3 2017 | 2017-10-25 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ICFI | ICF International, Inc. | Q1 2017 | 2017-05-06 | B+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| VRNS | Varonis Systems, Inc. | Q2 2016 | 2016-08-09 | B+ |
| NWSA | News Corporation | Q2 2016 | 2016-08-08 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
ULCC · Q1 2023 → YESThe question is: Does management ground their case in OBSERVED CUSTOMER OR COUNTERPARTY BEHAVIOR from the recent period? YES Management points to concrete recent-period behavior: over half of GoWild Pass sales so far are from customers with no prior travel history with Frontier, plus overwhelmingly positive feedback and customers taking the product to social media. They treat this observed adoption pattern as central proof that the offering is working and will keep growing, with the 90%+ repeat rate and $85–$100 per-passenger contribution goals still ahead of current results. They also cite the shift in consumer demand patterns (leisure travel increasingly favoring peak days, expanding RASM premium from 19% to over 25%) as direct evidence of customer preference that is reshaping capacity and margins. These elements are presented as the behavioral foundation for continued growth rather than merely company results or plans.
PCRX · Q4 2017 → YESThe question is: Does management ground their case for why the business is working and will keep growing in OBSERVED CUSTOMER OR COUNTERPARTY BEHAVIOR from the recent period? YES Management grounds its case in concrete, observed counterparty behavior—specifically J&J’s sales team activating accounts and training customers on EXPAREL technique, with the number of activated accounts continuing to grow, plus J&J committing to a six-fold increase in PEAK programs (already exceeding 2018 plans). They also cite commercial payers paying for EXPAREL under C9290 as a medical benefit and hospitals gaining access through surgeon relationships, treating these patterns as central proof that the offering is being chosen and valued, with the business still early and expanding ahead.
PPC · Q1 2024 → YESThe question is: Does management ground their case in OBSERVED CUSTOMER OR COUNTERPARTY BEHAVIOR from the recent period? YES Management grounds its case in observed counterparty behavior by citing concrete patterns such as key customers increasing marketplace presence, deli and QSRs showing steady performance, brands growing faster than category averages in Europe, key customer partnerships driving growth in Mexico, and key customers outpacing industry growth in domestic chicken volumes and value-added products — all presented as recent, specific actions by buyers and partners that demonstrate genuine preference and commitment, with the business still building further through continued diversification and new opportunities.